Amy Elazzouzi
Fortuna: 1 M $ al 31/07/2026
Fortuna: 1 M $ al 31/07/2026
Amy Elazzouzi is currently Director-Finance & Operations at Kew, Inc. and Secretary, Treasurer & Chief Accounting Officer at Aura Biosciences, Inc. Formerly, Ms. Elazzouzi was Controller at AVEO Pharmaceuticals, Inc. Education includes an MBA from Northeastern University and an undergraduate degree from Regis College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
AURA BIOSCIENCES INC 0,14 % | 01/09/2026 | 143.600 ( 0,14 % ) | 1 M $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| AURA BIOSCIENCES, INC. | Comptroller/Controller/Auditor | 25/10/2024 |
Kew, Inc.
Kew, Inc. Medical/Nursing ServicesHealth Services Provides oncology services | Director Financiero/CFO | - |
| Empresas | Cargo | Fin |
|---|---|---|
| AVEO PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Aura Biosciences, Inc.
Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Regis College
Regis College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops cancer therapeutics | Health Technology |
Kew, Inc.
Kew, Inc. Medical/Nursing ServicesHealth Services Provides oncology services | Health Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.